NasdaqGS - Nasdaq Real Time Price USD

Black Diamond Therapeutics, Inc. (BDTX)

Compare

2.5600

+0.0600

(+2.40%)

At close: December 13 at 4:00:02 PM EST

2.5500

-0.01

(-0.39%)

After hours: December 13 at 7:31:30 PM EST

US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

As the U.S. stock market experiences a pullback from its recent highs, investors are keeping a close eye on economic indicators and Federal Reserve actions that could influence future trends. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover opportunities in this unique segment of the market.

Simply Wall St. 2 days ago

BDTX
+2.40%
NAUT

III
Black Diamond: Q3 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Black Diamond Therapeutics, Inc. BDTX) on Tuesday reported a loss of $15.6 million in its third quarter.

Associated Press Finance last month

BDTX
+2.40%
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

As the U.S. stock market navigates the complexities of a presidential election and anticipated Federal Reserve rate decisions, investors are closely watching the movements of major indices like the Dow Jones and Nasdaq. In such a climate, penny stocks—though an older term—remain relevant for those seeking investment opportunities in smaller or newer companies. These stocks often offer potential value when supported by strong financials, presenting a unique opportunity for growth at lower...

Simply Wall St. last month

KLTR

VNDA

BDTX
+2.40%
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025Cash, cash equivalents, and investments of $112.7 million as

GlobeNewswire last month

BDTX
+2.40%
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024Pipe

GlobeNewswire last month

BDTX
+2.40%
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resou

GlobeNewswire 2 months ago

BDTX
+2.40%
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Monday, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC). “Patients often become resistant to osimertinib with the emergence of on-target resistance EGFR mutations,” said Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics. “Our preli

Benzinga 2 months ago

BDTX
+2.40%
AZN
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations Encouraging durability with DOR of approximately 8 months or more for first 3 patients with a PR; 14 of 19 patients remain on treatment Regulatory feedback on registration path anticipated in Q1 2025 Initial results of BDTX-1535 in first-line NSCLC patients with non-classical EGF

GlobeNewswire 2 months ago

BDTX
+2.40%
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET. Webcast information The webcast can be

GlobeNewswire 2 months ago

BDTX
+2.40%
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline chemotherapy and the remainder are treated with osimertinib or afatinib Short time to treatment discontinuation ranging from four to eight months demonstrates clear unmet need for patients with non-classical EGFR mutant NSCLC CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Black

GlobeNewswire 2 months ago

BDTX
+2.40%
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre’s Board of Directors (the “Board”), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. “We are th

GlobeNewswire 4 months ago

BDTX
+2.40%
GYRE
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy

Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 4 months ago

BDTX
+2.40%
Black Diamond: Q2 Earnings Snapshot

BDTX) on Tuesday reported a loss of $19.9 million in its second quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 36 cents. The results exceeded Wall Street expectations.

Associated Press Finance 4 months ago

BDTX
+2.40%
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and initial Phase 1 data of BDTX-4933 in KRASm NSCLC in Q4 2024Upcoming poster presentation at 2024 ESMO Congress in September, titled “Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients with Non-classical EGFR Mutations Demonstrates Hig

GlobeNewswire 4 months ago

BDTX
+2.40%
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 5 months ago

BDTX
+2.40%
Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry […]

Insider Monkey 5 months ago

BDTX
+2.40%
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology

GlobeNewswire 6 months ago

BDTX
+2.40%
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY. Presentation details are as follows: 7:30-7:55am ET on Wednes

GlobeNewswire 6 months ago

BDTX
+2.40%
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company

Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to...

Simply Wall St. 6 months ago

BDTX
+2.40%
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?

Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks 7 months ago

BDTX
+2.40%

Performance Overview

Return	BDTX	S&P 500
YTD	-8.90%	+26.86%
1-Year	-11.11%	+30.31%
3-Year	-57.12%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Black Diamond Therapeutics, Inc. (BDTX)

US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

Black Diamond: Q3 Earnings Snapshot

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy

Black Diamond: Q2 Earnings Snapshot

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company

Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?

Performance Overview